• Email Us: [email protected]
  • Contact Us: +1 718 874 1545
  • Skip to main content
  • Skip to primary sidebar

Medical Market Report

  • Home
  • All Reports
  • About Us
  • Contact Us

Newly Approved Schizophrenia Drug Could Eventually Treat Alzeimer’s-Related Psychosis

December 3, 2024 by Deborah Bloomfield

A drug that has recently been approved for the treatment of schizophrenia could one day be prescribed to Alzheimer’s patients. Researchers are trialing Cobenfy to see if it effectively treats Alzheimer’s-induced psychosis. However, there is still a fair way to go before we see if it will be approved as a treatment option for this particular condition. 

Cobenfy was approved for use in the treatment of schizophrenia by the US Food and Drug Administration (FDA) in late September. There has been a great deal of hype around the drug, which has been described as “the first new approach” to the treatment of schizophrenia in decades.   

Advertisement

Technically, it is not one but two drugs: Xanomeline and Trospium. Xanomeline was first developed in the 1990s and trialed in patients with Alzheimer’s disease, appearing to improve cognitive function and lower psychotic symptoms. However, it also triggered several nasty side effects in many patients, including nausea and vomiting, which led to it being shelved – at least, temporarily. Trospium is a muscarinic receptor-blocking drug that can’t traverse the blood-brain barrier, so the addition of that drug to the mix reduces the unpleasant side effects in the body.

Cobenfy has created a lot of excitement because it applies a new mechanism to treat schizophrenia – it targets muscarinic acetylcholine receptors, found in cell membranes. In particular, it targets two of these receptors: M4 and M1.

While Alzheimer’s and schizophrenia are completely different diseases, there are overlapping symptoms such as paranoia, and over half of those with Alzheimer’s will go on to develop psychotic symptoms. 

Cobenfy was first developed by Karuna Therapeutics, a company that has been bought by the New Jersey pharmaceutical company Bristol Myers Squibb (BMS). The company is currently running trials to see if the drug would benefit those experiencing psychosis as a result of Alzheimer’s. 

Advertisement

According to BioPharma Dive, the company is planning to begin late-stage testing next. In 2026, they project to have collected the results from two trials involving a combination of around 800 people who have psychosis caused by Alzheimer’s. According to PharmaVoice, if successful, it is thought the drug could make even more sales from Alzheimer’s patients than those with schizophrenia. 

The Alzheimer’s Association estimates 6.9 people in the US have Alzheimer’s. It is an extremely complex condition and there is currently no cure. However, researchers have recently announced exciting new developments that could pave the way for better treatments in the future, from novel theories that may change the way we think of the disease to new treatment options, including drugs and genetic therapy.

[H/t Nature.]

Deborah Bloomfield
Deborah Bloomfield

Related posts:

  1. No ‘magic wand’ to fix Lebanon crisis, new prime minister says
  2. Looking For A New Career In Tech? Get This CompTIA Training.
  3. Parker Solar Probe Finds The Source Of Fast Solar Wind Flurries
  4. Why Do Animals Have Different Pupil Shapes?

Source Link: Newly Approved Schizophrenia Drug Could Eventually Treat Alzeimer’s-Related Psychosis

Filed Under: News

Primary Sidebar

  • The Universe’s “Red Sky Paradox” Just Got Darker: Most Stars Might Never Host Observers
  • Uranus And Neptune May Not Be “Ice Giants” But The Solar System’s First “Rocky Giants”
  • COVID-19 Can Alter Sperm And Affect Brain Development In Offspring, Causing Anxious Behavior
  • Why Do Spiders’ Legs Curl Up Like That When They’re Dead?
  • “Dead Men’s Fingers” Might Just Be The Strangest Fruit On The Planet
  • The South Atlantic’s Giant Weak Spot In The Earth’s Magnetic Field Is Growing
  • Nearly Half A Century After Being Lost, “Zombie Satellite” LES-1 Began Sending Signals To Earth
  • Extinct In the Wild, An Incredibly Rare Spix’s Macaw Chick Hatches In New Hope For Species
  • HUNTR/X Or Giant Squid? Following Alien Claims, We Asked Scientists What They Would Like Interstellar Object 3I/ATLAS To Be
  • Flat-Earthers Proved Wrong Using A Security Camera And A Garage
  • Earth Breaches Its First Climate Tipping Point: We’re Moving Into A World Without Coral Reefs
  • Cheese Caves, A Proposal, And Chance: How Scientists Ended Up Watching Fungi Evolve In Real Time
  • Lab-Grown 3D Embryo Models Make Their Own Blood In Regenerative Medicine Breakthrough
  • Humans’ Hidden “Sixth Sense” To Be Mapped Following $14.2 Million Prize – What Is Interoception?
  • Purple Earth Hypothesis: Our Planet Was Not Blue And Green Over 2.4 Billion Years Ago
  • Hippos Hung Around In Europe 80,000 Years Later Than We Thought
  • Officially Gone: Slender-Billed Curlew, Once-Widespread Migratory Bird, Declared Extinct By IUCN
  • Watch: Rare Footage Captures Freaky Faceless Cusk Eels Lurking On The Deep-Sea Floor
  • Watch This Funky Sea Pig Dancing Its Way Through The Deep Sea, Over 2,300 Meters Below The Surface
  • NASA Lets YouTuber Steve Mould Test His “Weird Chain Theory” In Space
  • Business
  • Health
  • News
  • Science
  • Technology
  • +1 718 874 1545
  • +91 78878 22626
  • [email protected]
Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.

Powered by Prudour Network

Copyrights © 2025 · Medical Market Report. All Rights Reserved.

Go to mobile version